Stewart A Noble

US Patent:

6340683, Jan 22, 2002

Filed:

Apr 22, 1999

Appl. No.:

09/296332

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ
Stewart A. Noble - Upper Saddle River NJ
Mahesh N. Desai - Clifton NJ

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

C07D25150

US Classification:

514245, 544197, 544198, 544208, 544209

Abstract:

This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

US Patent:

6569856, May 27, 2003

Filed:

Jan 3, 2002

Appl. No.:

10/037859

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ
Stewart A. Noble - Upper Saddle River NJ
Mahesh N. Desai - Clifton NJ

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

C07D25150

US Classification:

514245, 544197, 544198, 544208, 544209

Abstract:

This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

US Patent:

6706716, Mar 16, 2004

Filed:

Jan 17, 2001

Appl. No.:

09/764710

Inventors:

Michael Konkel - Garfield NJ
John M. Wetzel - Fair Lawn NJ
Stewart A. Noble - Wheeling IL
Charles Gluchowski - Danville CA
Douglas A. Craig - Emerson NJ

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

A61P 4300

US Classification:

51425311, 51425312, 544360, 544365

Abstract:

This invention is directed towards a method of inhibiting activation of a human adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human adrenergic receptor. This invention provides for a compound which binds selectively to a human adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.

US Patent:

6720324, Apr 13, 2004

Filed:

Jul 5, 2001

Appl. No.:

09/899635

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ
John Wetzel - Fairlawn NJ
John E. DeLeon - North Bergen NJ
Bharat Lagu - Belle Mead NJ
Charles Gluchowski - Danville CA
Stewart Noble - Lake Forest IL
Dhanapalan Nagarathnam - Bethany CT

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

C07D23932

US Classification:

51425214, 514274, 544316

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

US Patent:

6989379, Jan 24, 2006

Filed:

Apr 21, 2000

Appl. No.:

10/009849

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Wai C. Wong - Hamden CT, US
Stewart A. Noble - Wheeling IL, US
Manesh N. Desai - Nutley NJ, US

Assignee:

H. Lundbick A/S - Volby-Copenhagen

International Classification:

C07D 513/04
C07D 513/22
A61K 31/381
A61P 3/04

US Classification:

51421111, 540548, 548151, 514366

Abstract:

This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

US Patent:

7189720, Mar 13, 2007

Filed:

Apr 6, 2005

Appl. No.:

11/099960

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Stewart A. Noble - San Diego CA, US
Mahesh N. Desai - Nutley NJ, US

Assignee:

H. Lundbeck A/S - Valby-Copenhagen

International Classification:

C07D 251/50
C07D 251/70
A61K 31/53
A61P 3/04

US Classification:

514245, 544197, 544198, 544208, 544209

Abstract:

This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

US Patent:

7271195, Sep 18, 2007

Filed:

Jun 10, 2004

Appl. No.:

10/865743

Inventors:

Paul L. Wash - San Diego CA, US
Brandon M. Wiley - Encinitas CA, US
Christian Hassig - San Diego CA, US
James W. Malecha - Libertyville IL, US
Stewart A. Noble - San Diego CA, US

Assignee:

Kalypsys, Inc. - San Diego CA

International Classification:

A61K 31/18
C07C 303/00

US Classification:

514602, 564 84, 564 88

Abstract:

Disclosed herein are carbonyl compounds of Formula I, II, or III, and others as described herein. Also disclosed are methods of treating disease, such as cancer, neurological disorders, including polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, autoimmune diseases and cardiovascular conditions, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

US Patent:

7273880, Sep 25, 2007

Filed:

Jan 20, 2005

Appl. No.:

11/040328

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Wai C. Wong - Hamden CT, US
Stewart A. Noble - San Diego CA, US
Yasuchika Yamaguchi - Guilford CT, US

Assignee:

H. Lunbeck A/S - Copenhagen-Valby
Novartis AG - Basel

International Classification:

A61K 31/426

US Classification:

514370

Abstract:

This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.